Does the media favor JNJ or NVO?

In the previous week, Johnson & Johnson had 59 more articles in the media than Novo Nordisk A/S. MarketBeat recorded 92 mentions for Johnson & Johnson and 33 mentions for Novo Nordisk A/S. Johnson & Johnson's average media sentiment score of 1.04 beat Novo Nordisk A/S's score of 0.53 indicating that Johnson & Johnson is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Johnson & Johnson 56 Very Positive mention(s) 13 Positive mention(s) 16 Neutral mention(s) 4 Negative mention(s) 3 Very Negative mention(s) Positive Novo Nordisk A/S 14 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 7 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor NVO or MRK?

In the previous week, Merck & Co., Inc. had 9 more articles in the media than Novo Nordisk A/S. MarketBeat recorded 42 mentions for Merck & Co., Inc. and 33 mentions for Novo Nordisk A/S. Merck & Co., Inc.'s average media sentiment score of 0.92 beat Novo Nordisk A/S's score of 0.53 indicating that Merck & Co., Inc. is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 14 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 7 Negative mention(s) 1 Very Negative mention(s) Positive Merck & Co., Inc. 28 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 3 Very Negative mention(s) Positive

Which has better earnings and valuation, NVO or NVS?

Novo Nordisk A/S has higher revenue and earnings than Novartis. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novo Nordisk A/S $333.65B 0.55 $15.51B $3.97 10.36 Novartis $54.53B 5.61 $13.98B $5.24 30.61

Is NVO or NVS more profitable?

Novo Nordisk A/S has a net margin of 33.99% compared to Novartis' net margin of 18.11%. Novo Nordisk A/S's return on equity of 53.52% beat Novartis' return on equity. Company Net Margins Return on Equity Return on Assets Novo Nordisk A/S 33.99% 53.52% 19.49% Novartis 18.11% 41.04% 14.45%

Does the media prefer NVO or NVS?

In the previous week, Novo Nordisk A/S had 12 more articles in the media than Novartis. MarketBeat recorded 33 mentions for Novo Nordisk A/S and 21 mentions for Novartis. Novartis' average media sentiment score of 0.71 beat Novo Nordisk A/S's score of 0.53 indicating that Novartis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 14 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 7 Negative mention(s) 1 Very Negative mention(s) Positive Novartis 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has preferable earnings & valuation, AZN or NVO?

Novo Nordisk A/S has higher revenue and earnings than AstraZeneca. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AstraZeneca $58.74B 4.90 $10.23B $7.07 26.24 Novo Nordisk A/S $333.65B 0.55 $15.51B $3.97 10.36

Does the media favor AZN or NVO?

In the previous week, Novo Nordisk A/S had 19 more articles in the media than AstraZeneca. MarketBeat recorded 33 mentions for Novo Nordisk A/S and 14 mentions for AstraZeneca. AstraZeneca's average media sentiment score of 1.25 beat Novo Nordisk A/S's score of 0.53 indicating that AstraZeneca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AstraZeneca 10 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novo Nordisk A/S 14 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 7 Negative mention(s) 1 Very Negative mention(s) Positive

Which has stronger valuation and earnings, NVO or PFE?

Novo Nordisk A/S has higher revenue and earnings than Pfizer. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novo Nordisk A/S $333.65B 0.55 $15.51B $3.97 10.36 Pfizer $62.58B 2.68 $7.77B $0.70 42.03

Is NVO or PFE more profitable?

Novo Nordisk A/S has a net margin of 33.99% compared to Pfizer's net margin of 6.34%. Novo Nordisk A/S's return on equity of 53.52% beat Pfizer's return on equity. Company Net Margins Return on Equity Return on Assets Novo Nordisk A/S 33.99% 53.52% 19.49% Pfizer 6.34% 19.88% 8.52%

Does the media prefer NVO or PFE?

In the previous week, Pfizer had 35 more articles in the media than Novo Nordisk A/S. MarketBeat recorded 68 mentions for Pfizer and 33 mentions for Novo Nordisk A/S. Pfizer's average media sentiment score of 0.64 beat Novo Nordisk A/S's score of 0.53 indicating that Pfizer is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 14 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 7 Negative mention(s) 1 Very Negative mention(s) Positive Pfizer 30 Very Positive mention(s) 7 Positive mention(s) 23 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive

Novo Nordisk A/S (NVO) Competitors

$41.13 +0.43 (+1.06%)

Closing price 11/11/2026 03:59 PM Eastern

Extended Trading

$40.85 -0.28 (-0.69%)

As of 11/11/2026 07:58 PM Eastern

Compare

NVO vs. JNJ, MRK, NVS, AZN, and PFE

Should you buy Novo Nordisk A/S stock or one of its competitors? Novo Nordisk A/S's main competitors and comparable companies include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Novartis (NVS), AstraZeneca (AZN), and Pfizer (PFE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Novo Nordisk A/S compare to Johnson & Johnson?

Johnson & Johnson (NYSE:JNJ) and Novo Nordisk A/S (NYSE:NVO) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

Novo Nordisk A/S has a net margin of 33.99% compared to Johnson & Johnson's net margin of 16.20%. Novo Nordisk A/S's return on equity of 53.52% beat Johnson & Johnson's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Johnson & Johnson	16.20%	31.64%	13.04%
Novo Nordisk A/S	33.99%	53.52%	19.49%

Johnson & Johnson has higher earnings, but lower revenue than Novo Nordisk A/S. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Johnson & Johnson	$94.19B	7.17	$26.80B	$6.60	42.50
Novo Nordisk A/S	$333.65B	0.55	$15.51B	$3.97	10.36

In the previous week, Johnson & Johnson had 59 more articles in the media than Novo Nordisk A/S. MarketBeat recorded 92 mentions for Johnson & Johnson and 33 mentions for Novo Nordisk A/S. Johnson & Johnson's average media sentiment score of 1.04 beat Novo Nordisk A/S's score of 0.53 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Johnson & Johnson	56 Very Positive mention(s)	13 Positive mention(s)	16 Neutral mention(s)	4 Negative mention(s)	3 Very Negative mention(s)	Positive
Novo Nordisk A/S	14 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	7 Negative mention(s)	1 Very Negative mention(s)	Positive

69.6% of Johnson & Johnson shares are held by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are held by institutional investors. 0.2% of Johnson & Johnson shares are held by insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Johnson & Johnson has a beta of 0.22, suggesting that its share price is 78% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market.

Johnson & Johnson currently has a consensus target price of $275.92, indicating a potential downside of 1.64%. Novo Nordisk A/S has a consensus target price of $59.44, indicating a potential upside of 44.52%. Given Novo Nordisk A/S's higher probable upside, analysts plainly believe Novo Nordisk A/S is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Johnson & Johnson	0 Sell rating(s)	8 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.73
Novo Nordisk A/S	5 Sell rating(s)	16 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.00

Johnson & Johnson pays an annual dividend of $5.36 per share and has a dividend yield of 1.9%. Novo Nordisk A/S pays an annual dividend of $0.81 per share and has a dividend yield of 2.0%. Johnson & Johnson pays out 81.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novo Nordisk A/S pays out 20.4% of its earnings in the form of a dividend. Johnson & Johnson has increased its dividend for 64 consecutive years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Johnson & Johnson beats Novo Nordisk A/S on 12 of the 20 factors compared between the two stocks.

How does Novo Nordisk A/S compare to Merck & Co., Inc.?

Novo Nordisk A/S (NYSE:NVO) and Merck & Co., Inc. (NYSE:MRK) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

Novo Nordisk A/S pays an annual dividend of $0.81 per share and has a dividend yield of 2.0%. Merck & Co., Inc. pays an annual dividend of $3.40 per share and has a dividend yield of 2.3%. Novo Nordisk A/S pays out 20.4% of its earnings in the form of a dividend. Merck & Co., Inc. pays out 350.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Merck & Co., Inc. has raised its dividend for 14 consecutive years. Merck & Co., Inc. is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Merck & Co., Inc. has lower revenue, but higher earnings than Novo Nordisk A/S. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$333.65B	0.55	$15.51B	$3.97	10.36
Merck & Co., Inc.	$65.01B	5.58	$18.25B	$0.97	151.83

Novo Nordisk A/S has a net margin of 33.99% compared to Merck & Co., Inc.'s net margin of 3.64%. Novo Nordisk A/S's return on equity of 53.52% beat Merck & Co., Inc.'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	33.99%	53.52%	19.49%
Merck & Co., Inc.	3.64%	16.73%	5.88%

11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 76.1% of Merck & Co., Inc. shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by company insiders. Comparatively, 0.2% of Merck & Co., Inc. shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Novo Nordisk A/S has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market. Comparatively, Merck & Co., Inc. has a beta of 0.13, meaning that its stock price is 87% less volatile than the broader market.

In the previous week, Merck & Co., Inc. had 9 more articles in the media than Novo Nordisk A/S. MarketBeat recorded 42 mentions for Merck & Co., Inc. and 33 mentions for Novo Nordisk A/S. Merck & Co., Inc.'s average media sentiment score of 0.92 beat Novo Nordisk A/S's score of 0.53 indicating that Merck & Co., Inc. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	14 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	7 Negative mention(s)	1 Very Negative mention(s)	Positive
Merck & Co., Inc.	28 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	3 Very Negative mention(s)	Positive

Novo Nordisk A/S currently has a consensus target price of $59.44, indicating a potential upside of 44.52%. Merck & Co., Inc. has a consensus target price of $155.74, indicating a potential upside of 5.75%. Given Novo Nordisk A/S's higher possible upside, equities analysts plainly believe Novo Nordisk A/S is more favorable than Merck & Co., Inc..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	5 Sell rating(s)	16 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.00
Merck & Co., Inc.	1 Sell rating(s)	11 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.59

Summary

Merck & Co., Inc. beats Novo Nordisk A/S on 12 of the 20 factors compared between the two stocks.

How does Novo Nordisk A/S compare to Novartis?

Novo Nordisk A/S (NYSE:NVO) and Novartis (NYSE:NVS) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Novo Nordisk A/S pays an annual dividend of $0.81 per share and has a dividend yield of 2.0%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 1.9%. Novo Nordisk A/S pays out 20.4% of its earnings in the form of a dividend. Novartis pays out 58.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

Novo Nordisk A/S has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market. Comparatively, Novartis has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market.

11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 13.1% of Novartis shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by insiders. Comparatively, 0.0% of Novartis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Novo Nordisk A/S has a net margin of 33.99% compared to Novartis' net margin of 18.11%. Novo Nordisk A/S's return on equity of 53.52% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	33.99%	53.52%	19.49%
Novartis	18.11%	41.04%	14.45%

Novo Nordisk A/S currently has a consensus target price of $59.44, indicating a potential upside of 44.52%. Novartis has a consensus target price of $152.25, indicating a potential downside of 5.08%. Given Novo Nordisk A/S's higher possible upside, equities research analysts clearly believe Novo Nordisk A/S is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	5 Sell rating(s)	16 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.00
Novartis	3 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.17

In the previous week, Novo Nordisk A/S had 12 more articles in the media than Novartis. MarketBeat recorded 33 mentions for Novo Nordisk A/S and 21 mentions for Novartis. Novartis' average media sentiment score of 0.71 beat Novo Nordisk A/S's score of 0.53 indicating that Novartis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	14 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	7 Negative mention(s)	1 Very Negative mention(s)	Positive
Novartis	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Novo Nordisk A/S has higher revenue and earnings than Novartis. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$333.65B	0.55	$15.51B	$3.97	10.36
Novartis	$54.53B	5.61	$13.98B	$5.24	30.61

Summary

Novo Nordisk A/S beats Novartis on 11 of the 18 factors compared between the two stocks.

How does Novo Nordisk A/S compare to AstraZeneca?

AstraZeneca (NYSE:AZN) and Novo Nordisk A/S (NYSE:NVO) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

20.4% of AstraZeneca shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Novo Nordisk A/S has a net margin of 33.99% compared to AstraZeneca's net margin of 17.68%. Novo Nordisk A/S's return on equity of 53.52% beat AstraZeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AstraZeneca	17.68%	31.85%	13.62%
Novo Nordisk A/S	33.99%	53.52%	19.49%

In the previous week, Novo Nordisk A/S had 19 more articles in the media than AstraZeneca. MarketBeat recorded 33 mentions for Novo Nordisk A/S and 14 mentions for AstraZeneca. AstraZeneca's average media sentiment score of 1.25 beat Novo Nordisk A/S's score of 0.53 indicating that AstraZeneca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AstraZeneca	10 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novo Nordisk A/S	14 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	7 Negative mention(s)	1 Very Negative mention(s)	Positive

Novo Nordisk A/S has higher revenue and earnings than AstraZeneca. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AstraZeneca	$58.74B	4.90	$10.23B	$7.07	26.24
Novo Nordisk A/S	$333.65B	0.55	$15.51B	$3.97	10.36

AstraZeneca pays an annual dividend of $2.17 per share and has a dividend yield of 1.2%. Novo Nordisk A/S pays an annual dividend of $0.81 per share and has a dividend yield of 2.0%. AstraZeneca pays out 30.7% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 20.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

AstraZeneca has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market.

AstraZeneca currently has a consensus price target of $206.67, indicating a potential upside of 11.38%. Novo Nordisk A/S has a consensus price target of $59.44, indicating a potential upside of 44.52%. Given Novo Nordisk A/S's higher probable upside, analysts clearly believe Novo Nordisk A/S is more favorable than AstraZeneca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AstraZeneca	0 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.84
Novo Nordisk A/S	5 Sell rating(s)	16 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Novo Nordisk A/S beats AstraZeneca on 11 of the 18 factors compared between the two stocks.

How does Novo Nordisk A/S compare to Pfizer?

Novo Nordisk A/S (NYSE:NVO) and Pfizer (NYSE:PFE) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

Novo Nordisk A/S has a net margin of 33.99% compared to Pfizer's net margin of 6.34%. Novo Nordisk A/S's return on equity of 53.52% beat Pfizer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	33.99%	53.52%	19.49%
Pfizer	6.34%	19.88%	8.52%

Novo Nordisk A/S has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market. Comparatively, Pfizer has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market.

In the previous week, Pfizer had 35 more articles in the media than Novo Nordisk A/S. MarketBeat recorded 68 mentions for Pfizer and 33 mentions for Novo Nordisk A/S. Pfizer's average media sentiment score of 0.64 beat Novo Nordisk A/S's score of 0.53 indicating that Pfizer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	14 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	7 Negative mention(s)	1 Very Negative mention(s)	Positive
Pfizer	30 Very Positive mention(s)	7 Positive mention(s)	23 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive

11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 68.4% of Pfizer shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by insiders. Comparatively, 0.6% of Pfizer shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Novo Nordisk A/S has higher revenue and earnings than Pfizer. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$333.65B	0.55	$15.51B	$3.97	10.36
Pfizer	$62.58B	2.68	$7.77B	$0.70	42.03

Novo Nordisk A/S presently has a consensus target price of $59.44, indicating a potential upside of 44.52%. Pfizer has a consensus target price of $30.39, indicating a potential upside of 3.30%. Given Novo Nordisk A/S's higher probable upside, analysts clearly believe Novo Nordisk A/S is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	5 Sell rating(s)	16 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pfizer	2 Sell rating(s)	13 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.19

Novo Nordisk A/S pays an annual dividend of $0.81 per share and has a dividend yield of 2.0%. Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 5.8%. Novo Nordisk A/S pays out 20.4% of its earnings in the form of a dividend. Pfizer pays out 245.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has increased its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Novo Nordisk A/S beats Pfizer on 10 of the 19 factors compared between the two stocks.

Get Novo Nordisk A/S News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVO vs. The Competition

Export

Metric	Novo Nordisk A/S	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$181.73B	$13.79B	$7.89B	$23.43B
Dividend Yield	1.97%	2.55%	2.45%	3.75%
P/E Ratio	10.36	25.99	34.27	25.47
Price / Sales	0.55	8.07	8.79	3.25
Price / Cash	8.68	15.68	22.08	15.86
Price / Book	5.48	5.04	4.45	3.73
Net Income	$15.51B	$2.87B	$3.50B	$1.08B
7 Day Performance	2.09%	2.86%	2.54%	2.53%
1 Month Performance	6.55%	-4.51%	-3.20%	1.23%
1 Year Performance	-18.16%	-6.37%	1.02%	6.57%

Novo Nordisk A/S Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVO Novo Nordisk A/S	4.03 of 5 stars	$41.13 +1.1%	$59.44 +44.5%	-16.4%	$181.73B	$333.65B	10.36	69,505	Trending News
JNJ Johnson & Johnson	3.6661 of 5 stars	$272.10 +2.2%	$275.92 +1.4%	+44.8%	$654.53B	$94.19B	41.20	138,200	Trending News
MRK Merck & Co., Inc.	4.4228 of 5 stars	$148.05 +2.3%	$155.74 +5.2%	+62.0%	$365.06B	$65.01B	152.55	75,000
NVS Novartis	4.0343 of 5 stars	$163.61 +2.7%	$152.25 -6.9%	+22.9%	$312.03B	$54.53B	31.21	75,267	Trending News Analyst Revision Gap Down
AZN AstraZeneca	4.7414 of 5 stars	$188.56 +2.5%	$206.67 +9.6%	+4.1%	$292.35B	$58.74B	26.66	96,100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NVO) was last updated on 11/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novo Nordisk A/S (NVO) Competitors

NVO vs. JNJ, MRK, NVS, AZN, and PFE

How does Novo Nordisk A/S compare to Johnson & Johnson?

Summary

How does Novo Nordisk A/S compare to Merck & Co., Inc.?

Summary

How does Novo Nordisk A/S compare to Novartis?

Summary

How does Novo Nordisk A/S compare to AstraZeneca?

Summary

How does Novo Nordisk A/S compare to Pfizer?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVO vs. The Competition

Novo Nordisk A/S Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novo Nordisk A/S (NVO) Competitors

NVO vs. JNJ, MRK, NVS, AZN, and PFE

How does Novo Nordisk A/S compare to Johnson & Johnson?

Is JNJ or NVO more profitable?

Which has stronger earnings & valuation, JNJ or NVO?

Does the media favor JNJ or NVO?

Do insiders and institutionals have more ownership in JNJ or NVO?

Which has more volatility and risk, JNJ or NVO?

Do analysts recommend JNJ or NVO?

Is JNJ or NVO a better dividend stock?

Summary

How does Novo Nordisk A/S compare to Merck & Co., Inc.?

Is NVO or MRK a better dividend stock?

Which has preferable earnings & valuation, NVO or MRK?

Is NVO or MRK more profitable?

Do institutionals & insiders believe in NVO or MRK?

Which has more risk and volatility, NVO or MRK?

Does the media favor NVO or MRK?

Do analysts recommend NVO or MRK?

Summary

How does Novo Nordisk A/S compare to Novartis?

Is NVO or NVS a better dividend stock?

Which has more volatility & risk, NVO or NVS?

Do insiders & institutionals believe in NVO or NVS?

Is NVO or NVS more profitable?

Do analysts prefer NVO or NVS?

Does the media prefer NVO or NVS?

Which has better earnings and valuation, NVO or NVS?

Summary

How does Novo Nordisk A/S compare to AstraZeneca?

Do insiders & institutionals have more ownership in AZN or NVO?

Is AZN or NVO more profitable?

Does the media favor AZN or NVO?

Which has preferable earnings & valuation, AZN or NVO?

Is AZN or NVO a better dividend stock?

Which has more risk & volatility, AZN or NVO?

Do analysts prefer AZN or NVO?

Summary

How does Novo Nordisk A/S compare to Pfizer?

Is NVO or PFE more profitable?

Which has more volatility and risk, NVO or PFE?

Does the media prefer NVO or PFE?

Do institutionals and insiders hold more shares of NVO or PFE?

Which has stronger valuation and earnings, NVO or PFE?

Do analysts rate NVO or PFE?

Is NVO or PFE a better dividend stock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVO vs. The Competition

Novo Nordisk A/S Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools